{"id":"imp-pioglitozone","safety":{"commonSideEffects":[{"rate":"5–10%","effect":"Weight gain"},{"rate":"5–10%","effect":"Fluid retention / edema"},{"rate":"variable","effect":"Hypoglycemia (when combined with other agents)"},{"rate":"5%","effect":"Headache"},{"rate":"2–5%","effect":"Myalgia"}]},"_chembl":{"chemblId":"CHEMBL5303438","moleculeType":null,"molecularWeight":"381.44"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"As a thiazolidinedione, pioglitazone binds to PPAR-γ in adipose tissue and muscle, enhancing insulin-mediated glucose uptake and reducing hepatic glucose production. This mechanism addresses insulin resistance, the underlying pathophysiology of type 2 diabetes, rather than stimulating insulin secretion directly.","oneSentence":"Pioglitazone activates peroxisome proliferator-activated receptor gamma (PPAR-γ) to improve insulin sensitivity and reduce blood glucose in type 2 diabetes.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:33:12.615Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT01134835","phase":"PHASE4","title":"PPAR-gamma: a Novel Therapeutic Target for Asthma?","status":"TERMINATED","sponsor":"University of Nottingham","startDate":"2010-06","conditions":"Asthma","enrollment":68}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":0,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"IMP Pioglitozone","genericName":"IMP Pioglitozone","companyName":"University of Nottingham","companyId":"university-of-nottingham","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Pioglitozone is an investigational medication that was studied in a clinical trial for asthma. However, the trial was terminated due to safety concerns with pioglitazone, which is a synonym for Pioglitozone.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}